Altemative splicing of the primary transcript of the CAK I gene in thyroid C-cells results predominantly in calcitonin (CT) mRNA (exons 14), whereas CGRP mRNA (exons I, 2, 3, 5, and 6) is mainly produced in neuronal cells. The CT mRNA encodes for a protein precursor containing an amino terminal peptide, CT, and a carboxyl terminal peptide (CCP I). CGRP ptecursor is composed of the same amino terminal peptide and CGRP. Recently we reported the presence of a third mature transcript of the C A E I gene in human medullary thyroid carcinoma (m) tissues. This transcript encodes for a ptecutsoE containing the amino terminal peptide CT and a novel carboxyl terminal peptide, CCP II. This fiiding was further confiimed in the "T-cell line de-rived from a human =. We produced monoclonal antibodies against CCP II and developed a rapid and specific immunofluorescence method for this peptide. We demonstrated CCP 11-specific immunoreactivity in 'IT-cells and in hiTC tissues. CCP 11 labeling was relatively homogeneous in contrast to CT and CGRP, which presented striking heterogeneity for intensity of labeling. Therefore, CCP 11 mRNA is translated in tumor cells in an apparently constitutive way. (J Histochem Cyrochem 41:1605-1610, 1993) 
Introduction
Endocrine and neuromodulator peptides are originally synthesized as large polypeptide precursors encoded by a mature mRNA. Some of these precursors are the source of as many as eight different bioactive peptides that must be excised from the precursor to become active (23). In addition, the primary transcript of a gene can generate, by alternative splicing, different mature "As encoding different protein precursors. Therefore, diversity in the production of bioactive peptides can occur at almost all levels of gene expression.
The primary transcript of the CALC I gene generates two distinct " As by alternative splicing (2,27). The calcitonin mRNA (exons 1, 2, 3, and polyadenylated exon 4) encodes for a protein precursor containing a N-terminal peptide, CT, and a 21 aminoacid CT carboxyl terminal peptide (called CCP I or katacalcin), human MTC (18). These cells have maintained properties of the parent tumor and produce high levels of both CT and CGRP (4,24). In this study we developed a rapid and specific immunofluorescence method for CCP I1 using monoclonal antibodies (MAb) directed against the eight specific amino acids of this peptide. All 'IT-cells stained homogeneously. Double-label immunofluorescence with antibodies against CCP IUCT and CCP II/CGRP revealed a relative heterogeneity for the intensity of intracellular CT and CGRP.
Materials and Methods

Cell Culture
The human MTC TT-cells have been previously described (18). The cells were cultured in RPMI 1640 medium buffered with 10 mM HEPES and supplemented with 10% fetal calf serum, 100 Ulml penicillin, 100 pglml streptomycin, 2.5 pglml fungizone. and 6 mM glutamine (all from Gibco; Cergy-Pontoise, France). Cells were plated at 20,000 cellslwell in eightwell Lab-Tek chamber slides (Nunc; Naperville, IL) and incubated at 37'C in a 95% humidified atmosphere with 5% CO2 for 4-6 days. The medium was changed every 48 hr.
Histological Method.
Cell Fixation. We have checked the effect of fixatives on specific immunostaining of CCP I1 in TT-cells. Different currently used fixatives were tested: ethanol 90%. formaldehyde 4% in PBS, pH 7.4, Carnoy, Bouin, and Bouin-Holland (modified Bouin solution containing copper acetate). Cells were rinsed with PBS, then immersed for 2 hr in the fixatives.
Before immunofluorescence studies, slides were rinsed as follows: (a) after ethanol fixation, slides were rehydrated through graded dilutions of ethanol, then rinsed in three baths of PBS (10 min each); (b) after formaldehyde fixation, slides were extensively rinsed in isotonic NaCI, then in three baths of PBS (10 min each); (c) after Carnoy fixation, slides were extensively washed in several baths of absolute ethanol, rehydrated through graded dilutions ofethanol, then rinsed in three baths of PBS (10 min each); and (d) after Bouin and Bouin-Holland fixation, slides were extensively rinsed in isotonic NaU, then in distilled water saturated with lithium chloride to remove picric acid (17) . and finally in three baths of PBS (10 min each).
Human MTC Tissues. Bouin-fixed paraffin sections (7 pm) prepared from MTC tissue obtained during surgery were deparaffinited in xylene (twice for 15 min), rehydrated through graded dilutions of ethanol, then extensively rinsed in three baths of PBS (10 min each). The histopathologic a l dugnosis was made on sections routinely stained with the Mann-Dominici procedure as previously reported (17) .
Antibody Production
The carboxyl terminal peptide fragment of CCP I1 (eight amino acids) containing the predicted CCP 11-specific sequence (8-CCP 11) was synthesized with an Applied Biosystems model 430A peptide synthesizer and conjugated to keyhole limpet hemocyanin (KLH) with benzidine as a coupling agent. Batches of six male Balblc mice 3 weeks of age were injected IP five times at 2-week intervals with 10 pg of the conjugate emulsified in Freund's adjuvant (Days 0, 14, 28,42, and 56). Two months later, mice received a last IV injection ofconjugate (Day 116) and were sacrificed on Day 119. The spleen was removed and the splenocytes were fused with the myeloma NS1 cell line using 40% PEG (3). The cells were then grown in 96-well tissue culture plates in a humidified 5% CO2 atmosphere at 37°C. The next day, selective hypoxanthine-aminopterine-thymidine medium was added to the plates. Supernatants were screened by ELISA for antibody production after 2 weeks of culture. After cloning by limiting dilution, the hybrid cells were implanted IP in Balblc nude (nulnu) mice and the resulting ascites fluid was collected after 10-14 days. MAb were purified from the ascites fluid by 50% ammonium sulfate precipitation at 4'C and protein A chromatography according to a published method (20).
Specific CT and CGRP immunodetection was performed with antihuman calcitonin (17, 29) and CGRP (11) polyclonal antibodies raised in sheep.
Immunohistochemistry
Immunodetection of CCP II. Lab-Tek slides were incubated overnight at 4'C with anti-CCP I1 MAb (diluted NO) in PBS containing 1% human albumin and 0.2 % 'Eton X-100 (incubation b a r ) . Slides were then washed in three baths of PBS (5 min each) and incubated for 3 hr at room temperature (RT) with fluorescein isothiocyanate (FIX)-conjugated donkey antimouse IgG (Jackson Immunoresearch West Grove, PA) diluted 1:50 in incubation buffer. Slides were finally rinsed as previously described and mounted in PBS-glycerol.
Immundetdon of CT and CGW. The same procedure was employed to detect CT and CGRP immunoreactivities. Anti-CT and anti-CGRP antibodies were used at 1:100 dilution in incubation buffer and incubated overnight at 4'C. Tetramethyl rhodamine isothiocyanate ("IC)-conjugated Controls for Specificity. The specificity of the CCP I1 immunostaining was tested with either specific MAb saturated overnight at 4'C with an excess of synthetic 8-CCP I1 (final concentration 400 pM) or affinitystripped MAb. To prepare the latter. synthetic 8-CCP I1 (300 pg) was co-valently linked to 1 g of cyanogen bromide-activated Sepharose 4B (Pharmacia; St Quentin en Yvelines. France), according to the manufacturer's instructions. Then 2 ml of MAb was diluted I:3 in 50 mM Tris-HCI (pH 7.5) and applied to the column for 90 min. according to the method of Mains and Eipper (19). The non-retained fraction was used as a negative control.
Photographs. The slides were mounted in buffered glycerin under glass coverslips and examined with a BH2 Olympus microscope equipped for epifluorescence illumination. Photographs were taken with a Tmax p3200 film (Kodak). Exposure times are indicated in the legends of the figures.
All TT-cells cultured for 4-6 days exhibited labeling for CT (Figure 2A) and CGRP ( Figure 2B ). The labeling intensity was variable, although often very strong. CCP I1 immunoreactivity was detected in the cytoplasm of TTcells ( Figure 3A ). This staining concerned all cells, with a relatively homogeneous intensity, and was specific, as confirmed by the great reduction of staining when cells were incubated with antibody preincubated with excess peptide ( Figure 3B) . Similarly, almost no staining was observed with an affinity-stripped CCP I1 antibody (data not shown). Slight nuclear staining sometimes appeared ( Figure  3A) , but not in all experiments.
Our CCP 11-specific MAb is not sensitive to the type of fixative used. Indeed, comparable results were obtained with the different fixatives: ethanol, Carnoy, Bouin, Bouin-Holland, and formaldehyde. However, formaldehyde-fixed TT-cells tended to exhibit a stronger positive signal which was not completely abolished by preincubation with an excess of synthetic immunogen.
The red fluorescence elicited by CT or CGRP staining was so strong that it could impress the photographic film when exposed with the fluorescein filter for the exposure time used for CCP I1 detection. Therefore, for the double-labeling experiments, we diluted twice more the anti-CT and anti-CGRP antibodies and verified that, in this way, the artifact was no longer observed (data not shown). Figure 4 shows 'IT-cells stained for either CCP I1 ( Figure   4A ) and CT ( Figure 4B ) or CCP I1 ( Figure 4C ) and CGRP ( Figure  4D ). The new dilution of CT and CGRP antibodies allowed detec- tion of very heterogeneous staining intensity for both peptides. Some cells contained high levels of CT or CGRP immunoreactivities and others were slightly stained, whereas CCP I1 labeling in the same cells was relatively homogeneous.
CCP I1 immunoreactivity was observed in MTC tissue ( Figure  5A ). As in TT-cells, staining was relatively homogeneous within the tumor. No staining was elicited by the antibody stripped on an affinity column specific for the synthetic immunogen (Figure 5B ).
Discussion
Studies on CALC I gene expression in human MTC (22) and TT cells (1) have shown the existence of a new CT mRNA composed of exons 1 , 2 , 3 . part of exon 4 (exon 4'), exon 5, and polyadenylated exon 6 . The junction between exon 4' and exon 5 changes the open reading frame and introduces a non-sense codon eight amino acids after the beginning of exon 5. This arrangement, which prevents translation of CGRP, predicts the existence of a new CT carboxyl terminal peptide, CCP 11, diverging in its last eight carboxyl terminal amino acids from CCP I (Figure 1 ). Specific immunostain-ing of CCP I1 with an MAb directed against its eight carboxyl terminal amino acids clearly suggests that this new transcript is actively translated in TT-cells and in MTC tissues. Fluorescence was almost completely abolished when the antibody was pre-incubated with synthetic immunogen and when the antibody was stripped on a CCP I1 affinity column. Furthermore, different ELISA experiments showed that the antibody does not crossreact with CCP I or CT (data not shown).
CCP 11-immunoreactive material can be either CCP I1 peptide or unprocessed CCP I1 precursor. For example, the BEN lung carcinoma cell line secretes high molecular weight forms of CT, reflecting absence or limited activity of proteolytic processing enzymes (26). However, Gkonos et al. (12) have shown that mature CT and CGRP are major secretory products of TT-cells, suggesting that, as in the rat, cleavage of N-terminal peptide occurs first, followed by cleavage of CCP I and amidation of CT (5) . Both CCP I1 and CCP I N-terminal regions are flanked in their respective precursors by the amidation cleavage signal Gly-Lys-Lys-Arg. Therefore, immunoreactive CCP I1 probably corresponds to mature peptide processed from its precursor with equal amounts of CT and N-terminal peptide. We are presently developing a rapid and spe- cific ELISA assay for CCP I1 which will be a useful tool to answer these questions.
All TT-cells contain simultaneous CT, CGRP, and CCP I1 immunoreactivities. However, several differences exist. First, CCP I1 detection required larger quantities of antibody and longer exposure time for photographs than CT and CGRP. This could reflect the production of lesser amounts of CCP I1 by 'IT-cells. In the same way, Adema and Baas (1) reported that CCP I1 mRNA is present at approximately 25% of the level of CT mRNA. However, as a number of factors, including the avidity of the antigenlantibody interaction, can modulate the labeling intensity, only a quantitative assay could confirm this hypothesis. Second, CCP I1 biosynthesis in TT-cells seems to be constitutive, in contrast to CT and CGRP. When the CCP I1 antibody was diluted from 1:20 to 1:50, the labeling intensity was fainter but still homogeneous (data not shown). Conversely, at highest dilution CT and CGRP antibodies revealed a striking heterogeneity, suggesting intercellular differences in storage for these peptides. An increasing heterogeneity of the cellular distribution of CT during growth was also observed by Berger et al. (4) in the parent TT-cell line and in two clones (high CT producer and low CT producer) derived from this cell line. A reversibility of the CALC I gene RNA processing choice has been demonstrated during TT-cell growth. For the first 2-3 days after seeding, CGRP mRNA levels are low, relative to CT mRNA. During logarithmic growth phase, CGRP mRNA levels rise severalfold and CT mRNA levels are stable. In postconfluent cells, CGRP mRNA levels fall, whereas CT mRNA levels are strongly increased (24). Our study was performed on cells grown for 4-6 days after seeding. At this stage cells were in logarithmic growth phase. It would be of interest to determine whether posttranscriptional processing events leading to CCP I1 mRNA are also regulated during cell growth. Indeed, although the order of the splicing reactions yielding to CCP I1 mRNA is still unknown, it is possible that a key intermediate RNA common to CT, CGRP, and CCP I1 mRNAs is the target of regulation of specific splicing (7) .
The formation of CCP I1 mRNa is restricted to humans, as the 5' splice donor site of exon 4' was not found in other species (22). It can be postulated that the essential function of CCP I and CCP I1 is the correct positioning of CT precursor during posttranslational processing. However, we cannot exclude the existence of another functional role for these peptides.
In conclusion, immunocytochemistry allowed us to demonstrate the presence of CCP I1 in TT cells, which was first predicted by mRNA studies (1) . The method we developed with a CCP 11-specific MAb will complete other studies to elucidate the regulation of the expression of CCP I1 peptide from CALC I primary transcript.
